Literature DB >> 21053107

Statins and renal disease: friend or foe?

Abhishek Deshmukh1, Jawahar L Mehta.   

Abstract

The role of statins in the treatment and prevention of cardiovascular diseases, such as coronary artery disease, acute coronary syndromes, diabetes, or stroke, is well established. However, there are still some questions regarding the role of statins in patients with chronic kidney disease (CKD). Dyslipidemia is a known cardiovascular risk factor in individuals without CKD. In these patients, however, the relation of dyslipidemia to cardiovascular risk is complex, and the underlying pathobiological mechanisms are complex. Statins have proven to be highly effective in patients with initial stages of CKD; however, their effects in patients with advanced-stage CKD have been neutral despite a low-density lipoprotein cholesterol-lowering effect. In this review, we summarize the findings of the recent clinical trials of statins in renal disease and make recommendations for our patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21053107     DOI: 10.1007/s11883-010-0140-5

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  29 in total

Review 1.  Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.

Authors:  Giovanni F M Strippoli; Sankar D Navaneethan; David W Johnson; Vlado Perkovic; Fabio Pellegrini; Antonio Nicolucci; Jonathan C Craig
Journal:  BMJ       Date:  2008-02-25

Review 2.  HMG CoA reductase inhibitors (statins) for dialysis patients.

Authors:  Sankar D Navaneethan; Sagar U Nigwekar; Vlado Perkovic; David W Johnson; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

3.  Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.

Authors:  Michel Chonchol; Thomas Cook; John Kjekshus; Terje R Pedersen; JoAnn Lindenfeld
Journal:  Am J Kidney Dis       Date:  2007-03       Impact factor: 8.860

4.  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Authors:  Folkert W Asselbergs; Gilles F H Diercks; Hans L Hillege; Ad J van Boven; Wilbert M T Janssen; Adriaan A Voors; Dick de Zeeuw; Paul E de Jong; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

5.  Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis.

Authors:  Kamyar Kalantar-Zadeh; Deborah L Regidor; Csaba P Kovesdy; David Van Wyck; Suphamai Bunnapradist; Tamara B Horwich; Gregg C Fonarow
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

6.  Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients.

Authors:  Vittorio E Andreucci; Rachel B Fissell; Jennifer L Bragg-Gresham; Jean Ethier; Roger Greenwood; Mark Pauly; Volker Wizemann; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

7.  Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.

Authors:  Bernard M Y Cheung; Ian J Lauder; Chu-Pak Lau; Cyrus R Kumana
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

8.  CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004.

Authors:  Adam T Whaley-Connell; James R Sowers; Lesley A Stevens; Samy I McFarlane; Michael G Shlipak; Keith C Norris; Shu-Cheng Chen; Yang Qiu; Changchun Wang; Suying Li; Joseph A Vassalotti; Allan J Collins
Journal:  Am J Kidney Dis       Date:  2008-04       Impact factor: 8.860

9.  Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Valentine Charlton-Menys; David A DeMicco; John H Fuller
Journal:  Am J Kidney Dis       Date:  2009-06-21       Impact factor: 8.860

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.